(Alliance News) - AstraZeneca PLC on Thursday said tests have confirmed effectiveness against Covid-19 from a one-time intramuscular dose of AZD7442 in high-risk populations.
The Cambridge, England-based pharmaceutical firm said new data from the AZD7442 Covid-19 Provent prevention and Tackle outpatient treatment phase III trials showed one 300 milligramme dose of AZD7442 reduced the risk of developing symptomatic Covid-19 compared to placebo by 83%.
The AZD7442 Provent trial is the first phase III trial designed to evaluate a monoclonal antibody for pre-exposure prophylaxis of symptomatic Covid-19, with targeted inclusion of high-risk and immunocompromised participants.
Astra highlighted that there were no cases of severe Covid-19 or Covid-19-related deaths in those treated with AZD7442 at either the primary or six-month analyses.
Meanwhile, an exploratory analysis of the Tackle outpatient treatment trial, in patients with mild-to-moderate Covid-19, showed that one 600mg dose of AZD7442 reduced the risk of developing severe Covid-19 or death by 88% compared to placebo in patients who had been symptomatic for three days or less at the time of treatment.
Astra noted that in both Provent and Tackle, AZD7442 was generally well tolerated.
The company said it has agreed to supply the US government with 700,000 doses of AZD7442 if granted an emergency use authorization by the US Food & Drug Administration, and it also has agreements to supply to other countries.
Astra shares were trading 0.7% lower in London on Thursday morning at 8,532.00 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)
